Loading quotes...

Forecast

The analysts' average price target is €43.16 (+12.95%). The median is €42.90 (+12.27%).

Buy	24
Hold	21
Sell	4

News Go to news feed

Teva Pharmaceuticals: FDA approves WELTRUZA for US without physician supervision

The FDA on October 9, 2026 approved the schizophrenia treatment WELTRUZA for the US market. The monthly injection replaces daily pills and requires no physician supervision. Teva Pharmaceuticals is increasingly focusing on specialty medicines under its “Pivot to Growth” strategy and is targeting up to $16.8 billion in sales for 2026. » More on finanzen.net
Teva accelerates pivot to growth as branded drugs and biosimilars drive outlook

Teva says its 'Pivot to Growth' strategy is entering a faster phase as branded medicines gain momentum, generics stabilize and biosimilars expand. Management highlighted AUSTEDO's potential to exceed $3 billion, AJOVY approaching $1 billion, and UZEDY plus long‑acting olanzapine representing a $1.5–2 billion opportunity. The company has 11 biosimilars on the market with about nine more planned by decade-end and expects to beat its $800 million biosimilars target for 2027 early. Teva also reduced debt, secured investment‑grade ratings ahead of schedule, completed refinancing, and is advancing pipeline assets including ecopipam and duvakitug toward potential 2027 launches. » More on finance.yahoo.com
S&P upgrades Teva to BBB- after debt reduction and strong branded pipeline

S&P Global Ratings has upgraded Teva from BB+ to BBB- and raised all of the company’s ratings. The agency cites ongoing debt reduction, stabilization in the generics business and growth of high-margin branded products; leverage is expected to fall from about 4x in the second quarter to the mid-3x range by year-end. S&P expects strong adjusted operating cash flow of $2.3–2.5 billion annually, substantial cost savings through 2027, as well as revenue gains from key brands such as Austedo, Ajovy and Uzedy and important product launches in the coming years. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2017, Teva Pharmaceuticals has already paid €0.66 in dividends. The last payout was in December 2017.

Financials

In the last quarter, Teva Pharmaceuticals had revenue of €3.88B and net profit of €205.7M

(EUR)	September 2026	YoY
Revenue	3.88B	1.64%
Gross profit	2.15B	9.72%
Net profit	205.7M	44.25%
EBITDA	481.15M	48.85%

Fundamentals

Metric	Value
Market capitalization	€44.38B
Number of shares	1.17B
52-week high/low	€38.74 - €21.43
Dividends	No
Beta	0.84
P/E ratio	94.69
PEG ratio	-3.31
P/B ratio	6.23
P/S ratio	2.88

Company profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Name	Teva Pharmaceuticals
CEO	Richard D. Francis
Headquarters	Tel Aviv, ta USA
Website	tevapharm.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	02/16/1982
Employees	32,008